Amedisys Inc (AMED): Price and Financial Metrics


Amedisys Inc (AMED)

Today's Latest Price: $313.54 USD

10.64 (3.51%)

Updated Jan 22 4:00pm

Add AMED to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 77 in Medical - Services

See all "A" rated Strong Buy stocks

AMED Stock Summary

  • AMED has a market capitalization of $9,938,312,263 -- more than approximately 82.46% of US stocks.
  • AMED's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 571.54 -- higher than 93.32% of US-listed equities with positive expected earnings growth.
  • The price/operating cash flow metric for Amedisys Inc is higher than 85.54% of stocks in our set with a positive cash flow.
  • If you're looking for stocks that are quantitatively similar to Amedisys Inc, a group of peers worth examining would be ATR, JHG, EHC, MORN, and BKI.
  • Visit AMED's SEC page to see the company's official filings. To visit the company's web site, go to www.amedisys.com.

AMED Stock Price Chart Interactive Chart >

Price chart for AMED

AMED Price/Volume Stats

Current price $313.54 52-week high $314.41
Prev. close $302.90 52-week low $132.95
Day low $301.91 Volume 214,000
Day high $314.41 Avg. volume 181,479
50-day MA $271.53 Dividend yield N/A
200-day MA $230.00 Market Cap 10.29B

Amedisys Inc (AMED) Company Bio


Amedisys provides home health and hospice care services. It operates through two segments, Home Health and Hospice. The company was founded in 1982 and is based in Baton Rouge, Louisiana.

AMED Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$313.54$258.39 -15%

We started the process of determining a valid price forecast for Amedisys Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Amedisys Inc ranked in the 47th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for AMED, they are:

  • Interest coverage, a measure of earnings relative to interest payments, is 16.91; that's higher than 78.63% of US stocks in the Healthcare sector that have positive free cash flow.
  • The business' balance sheet reveals debt to be 4% of the company's capital (with equity being the remaining amount). Approximately merely 14.94% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • AMED's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 44.96% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-16%
1%-16%
2%-15%
3%-14%
4%-13%
5%-12%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as AMED, try BDX, FGEN, IQV, INBP, and PAHC.


AMED Latest News Stream


Event/Time News Detail
Loading, please wait...

AMED Latest Social Stream


Loading social stream, please wait...

View Full AMED Social Stream

Latest AMED News From Around the Web

Below are the latest news stories about Amedisys Inc that investors may wish to consider to help them evaluate AMED as an investment opportunity.

Barclays Stick to Their Buy Rating for Amedisys Inc By Investing.com

Barclays Stick to Their Buy Rating for Amedisys Inc

Investing.com | January 17, 2021

Amedisys, Inc. (NASDAQ:AMED) Shares Could Be 34% Above Their Intrinsic Value Estimate

Does the January share price for Amedisys, Inc. ( NASDAQ:AMED ) reflect what it's really worth? Today, we will estimate...

Yahoo | January 17, 2021

Phirbo (PAHC) Nutritional Specialty Aids Growth, Low ASP Ails

Phirbo's (PAHC) net vaccine sales remain robust on higher international demand for poultry vaccines.

Yahoo | January 12, 2021

Abbott (ABT) to Expand in Booming TBI Space on New Approval

If positive, Abbott's (ABT) TBI blood test result complements CT scans to help evaluate whether a suspected patient has a TBI.

Yahoo | January 12, 2021

Hologic (HOLX) to Expand in Oncology With Biotheranostics Buyout

Hologic (HOLX) aims to strengthen its Diagnostics business by foraying into the oncology adjacency space via the acquisition of Biotheranostics.

Yahoo | January 8, 2021

Read More 'AMED' Stories Here

AMED Price Returns

1-mo 8.18%
3-mo 24.86%
6-mo 46.01%
1-year 73.86%
3-year 461.60%
5-year 713.76%
YTD 6.89%
2020 75.73%
2019 42.53%
2018 122.18%
2017 23.65%
2016 8.42%

Continue Researching AMED

Here are a few links from around the web to help you further your research on Amedisys Inc's stock as an investment opportunity:

Amedisys Inc (AMED) Stock Price | Nasdaq
Amedisys Inc (AMED) Stock Quote, History and News - Yahoo Finance
Amedisys Inc (AMED) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8246 seconds.